Tin tức & Cập nhật

Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).

A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.

Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.